ARA-290 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
The half-life of ARA-290 is approximately 24 hours. This means dosing once daily is typical to maintain stable levels. The half-life directly affects how long ARA-290 remains active and influences optimal injection timing.
What Is the Half-Life of ARA-290?
The half-life of ARA-290 is approximately 24 hours. This is the time it takes for blood concentration to drop by 50% after administration.
Understanding half-life is essential for designing effective dosing protocols — it determines how often you need to administer ARA-290 to maintain therapeutic blood levels.
What Does ARA-290's Half-Life Mean for Dosing?
With a half-life of approximately 24 hours, ARA-290 requires dosing once daily to maintain stable levels. The standard dosage of 2-4 mg daily via subcutaneous injection accounts for this pharmacokinetic profile.
After approximately 4-5 half-lives, ARA-290 reaches steady-state concentration — the point where the amount being absorbed equals the amount being eliminated. For ARA-290, this occurs within the first few days of consistent dosing.
When Is the Best Time to Inject ARA-290?
Optimal timing depends on your research goals. A half-life of approximately 24 hours means peak blood levels occur shortly after injection and decline predictably.
Common timing approaches: morning injection for daytime activity, pre-bed injection for overnight effects, or split dosing (once daily) for more stable levels throughout the day.
How Does ARA-290's Half-Life Compare to Similar Peptides?
ARA-290 is a Innate repair receptor agonist, anti-inflammatory peptide. Its half-life of approximately 24 hours positions it with a shorter duration of action compared to some alternatives in this class.
Shorter half-lives require more frequent dosing but allow for more precise control. Longer half-lives are more convenient but carry risk of accumulation.
Calculate Your ARA-290 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for ARA-290.
Open Calculator →Bottom Line: ARA-290 Half-Life and Dosing
ARA-290 has a half-life of approximately 24 hours, supporting the standard protocol of 2-4 mg daily dosed once daily over 28 days typical; 8-16 weeks for extended response.
Read our ARA-290 dosage guide for complete protocol details.
Complete Guide
ARA-290 : Benefits, Dosage, Side Effects & Research
Related Reading
- ARA-290 Dosage Guide
- ARA-290 Benefits
- ARA-290 Side Effects
- ARA-290 Stacking Guide
- ARA-290 Cycle Guide
- ARA-290 Research
Research-Grade Sourcing
If you're going to research ARA-290, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is ARA-290?
ARA-290 (Erythropoietin-derived tissue-protective peptide) is a Innate repair receptor agonist, anti-inflammatory peptide. Synthetic 11-amino acid peptide engineered from the tissue-protective domain of erythropoietin (EPO). It is researched for neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes.
What is the recommended ARA-290 dosage?
Common dosages: 2-4 mg daily administered once daily via subcutaneous injection. Cycle length: 28 days typical; 8-16 weeks for extended response. Half-life: approximately 24 hours. Use our peptide calculator for exact reconstitution math.
What are the side effects of ARA-290?
Safe profile in multiple clinical trials. Minimal reported adverse events. Occasional mild injection site reactions. No serious safety concerns identified across diabetes, sarcoidosis, and neuropathy patient populations.
Is ARA-290 safe?
ARA-290 has shown a preliminary safety profile in research. Investigational. Underwent Phase II clinical trials. Not FDA-approved. All research should follow appropriate safety protocols.